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ABSTRACT 
Background and Objectives: Loss to follow-up is a common problem of most patients on antiretroviral therapy in Ethiopia. Second-line 
antiretroviral therapy is the drug that would be used when the first-line therapy fails.  Thus this study intends to determine the incidence and 
risk factors of time to losses to follow up among  Human  Immunodeficiency  Virus (HIV) patients on second line regimens of  Antiretroviral 
Therapy(ART) in Amhara region Hospitals, Ethiopia.  
Methods: Institutional based retrospective cohort study was conducted in the Amhara region hospitals from February to March 2016. A total of 
1246 patient from eight hospitals in Amhara region were selected using simple random sampling method and data were extracted from patient 
charts.  The log rank test was used to assess presence of significant difference in time to losses to follow among levels of categorical variables. 
Both bi-variiable and multivariable Cox proportional hazards models were used to identify factors that affect the time to losses to follow up.     
Results: The cumulative incidence of loss to follow up was 5.41% over the entire (eight) years of follow-up. The cumulative incidence rates of 
death and transfer out were 10.99% and 10.02 %, respectively. In multivariable Cox regression analysis, ambulatory functional status 
(AHR=0.1967, 95% CI: 0.049- 0 .794), male gender (AHR=2.135, 95% CI: 1.053- 4.330), and adherence to ART (AHR=0.442, 95% CI: 0.198- 
0.989) were significant predictors of time to losses to follow up. The use of 2a, 2e and 2g types of second line regimen reduced the risk of  loss to 
follow up.   
Interpretations and Conclusions: The incidence of loss to follow up in Amhara region hospitals was low. Loss to folow up was negatively  
associated with female gender, ambulatory  baseline functional status, adherence, and types of second line regimen types. Further research on 
the effect of  types of drug is recommended by acertaining whether the reduction in loss to follow up  for patients who took drug types of 2a, 2e, 
and 2g is associaed with improved or worsened health outcomes by trafcking lost patients closely.        
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INTRODUCTION 
Since its introduction, Antiretroviral therapy (ART) has 
transformed the responses and emphasis that countries gave 
to HIV/AIDS and resulted in  an improvement of health1.  It 
has also brought a remarkable reduction in the transmission 
of HIV and HIV-related morbidity and mortality worldwide2.     
At the end of 2012, 10 million more people were receiving 
ART in low- and middle-income countries3. In 2015, about 
65% (15 million) of the total number of people living with 
the virus worldwide were receiving treatment for the 
HIV/AIDS3. However, even though there has been a 
continually increasing access to ART, still there are 
disparities across regions or countries.  
When the first-line antiretroviral therapy fails, HIV patient 
would be recommended to take the second-line therapy4. It 
has been shown that patients loss to follow-up (LTFU) affects 
the quality of care that patients could get. Loss to follow up is 
defined as not taking ART refill for a period of 3 months or 
longer from the last attendance for refill and not yet 
classified as ‘dead’ or ‘transferred-out’ in second line 
regimens ART.It also affects the evaluation of ART 
programmes in developing countries5. A systematic review 
done in sub-Saharan Africa about ART programmes showed 
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that the cumulative incidences of loss to follow-up of 
patients were 19%, 24% and 31% at 6, 12, and 24 months 
since the initiation of their treatment, respectively5.   
Many studies conducted in many parts of the world indicate 
different results regarding the risk factors of loss to follow 
up (LTFU). A study done in India showed that the incidence 
of LTFU is 15.5%6. A study conducted in Sub-Saharan African 
showed that the incidence loss to follow up is 17.7%7. The 
incidences of lost follow-up in ART were 15.6%, 27%, and 
36.6% for studies done in southeastern Nigeria8, South 
Africa9, and Cameron10, respectively. Studies done in 
Ethiopia showed that, the incidence of LTFU were 21.7%, 
14.5%, 19.6% in southern Ethiopia hospitals11, Hadiya zone 
(Southern Nations, Nationalities and Peoples Region)12, and 
Ethiopian public hospital clinics13, respectively. 
In Ethiopia, one of the major problems in ART programme is 
loss to follow up. A study done in southern Ethiopia11, Rural 
Ethiopia hospitals14, and Ethiopian public hospital clinics13 
showed that the incidence LTFU were 21.7%, 28.4%, and 
19.6%, respectively.  
A lot of factors were found to be associated with time-to-
LTFU including socio demographic factors like educational 
status, sex, Age, occupational 6,10,14,16-18  and clinical 
characteristics like Weight, Height, measures of  number of T 
helper cells ( CD4 )count, hemoglobin level, Adherence, WHO 
stage, Functional status, second line regimen drug, Co-
trimoxazole preventive therapy,  Opportunistic infections, 
Body mass index 6,7,9-11,17. Functional status of a patient was 
categorized as “working” if their daily activities were not 
altered due to illness, “ambulatory” if the patient was not 
fully working but was able to do minor tasks at home, and 
“bed ridden” when the patient remained in bed most of the 
time. 
A better understanding of the risk factors associated with 
loss to follow up in Ethiopia could be helpful to design 
interventions to reduce LTFU in patients who initiate ART. 
While evidences have proven that ART improves the survival 
time and quality of life of HIV patients, several clinical 
characteristics and socio demographic factors contributing 
to this high loss to follow up are not well understood in 
Ethiopia. 
However, research studies investigating predictors of loss to 
follow up after ART initiations are scarce in Amhara Region. 
A better understanding of the risk factors associated with 
loss to follow up in the region could be helpful to design 
interventions to reduce Loss to Follow Up in patients who 
initiate ART.  
MATERIALS AND METHODS 
Study design and setting  
A retrospective follow up study was conducted among adults 
living with HIV/AIDS and enrolled for second line ART 
regimens services in Amhara Regional State Hospitals from 
February 2008 - February 2016. Amhara region is one of the 
nine ethnic divisions of Ethiopia. The capital city of Amhara 
region is Bahir Dar. Report from EDHS showed that there are 
about 37,637 peoples who are living with HIV in Amhara 
region and it was 1.6%. According to Health and Health 
Related Indicators published by Federal Ministry of Health, 
the region has 17 Hospitals, 520 Health Centers and 2,941 
Health Posts. Of the 17 hospitals in the region, eight hospitals 
were selected by simple random sampling technique that 
included University of Gondar referral hospital, Felege Hiwot 
referral hospital, Dessie referral hospital, Woldia general 
hospital, Debre Markos referral hospital, Debre Tabor 
general hospital, Finote Salem general hospital, and Debre 
Birhan referral hospital. 
Sample size determination 
The sample size for the first objective was calculated by 
using a single population proportion formula and taking the 
assumptions of 95% confidence level, margin of error as 5%, 
incidence of loss to follow up 19.6% which was taken from a 
study done in Ethiopian public hospital clinic13, and a design 
effect of 2. Finally, we have got a sample size of 484 persons 
on second line ART.  
The sample size for the second objective was calculated by 
using double population proportion for survival analysis as: 
 
 
Where P1 is the proportion of CD4 count greater than or 
equal to >=100 (60.3%)  
P2 the proportion of CD4 count Less than <100 (37.8%) ; d is 
that probability of observing the event (19.6%) ; b=2.36 is 
logarithm of hazard ratio square  
Hazard ratio of CD4 count <100 is 2.36 when CD4 count 
>=100 is as reference 
Sampling procedure 
Eight hospitals were selected using simple random sampling 
from 17 hospitals found in the Amhara region. ART data of 
HIV patients who initiated the treatment since February 
2008 to February 2016 were retrospectively followed.  
Because, the maximum sample size determined is closer to 
the total number of ART in the eight Hospitals, we had taken 
all patients initiated the second line treatment in the 
specified period and hospitals (Figure 1).  
The dependent variable was time LTFU while the following 
factors were included in the model as independent variables: 
Socio demographic and anthropometric and clinical factors: 
Sex , Age, Educational status, occupation,  Weight, Height, 
CD4 count, hemoglobin level, Adherence, WHO stage, 
Functional status, second line regimen drug, Co-trimoxazole 
preventive therapy, INH, Opportunistic infections, Body mass 
index.
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Figure 1: Schematic presentation of sampling procedure of Second line ART users in Amhara region hospitals, Ethiopia, 2016 
 
Data collection procedure and quality control 
Data were extracted from standard medical registration 
books that were already recorded routinely by the data clerk 
at each hospital. These records were adopted by the National 
Center for AIDS and STD Control and Ministry of Health and 
were available at the ART centers. The data were collected 
by experienced ART programme who were trained on 
comprehensive HIV care and who were working in the ART 
clinic at selected hospitals. A supervisor was supervising the 
process of data collection. 
To ensure the quality of data, data collectors who were 
clinical nurses by profession and were working in ART 
programs were selected.  Moreover, about 5% of 
questionnaires were pre-tested seven days before the actual 
data collection was started. During data collection, close 
supervision was conducted by supervisors and principal 
investigator, by observing how the data collectors run and 
the collected data was checked for the completeness, 
accuracy and clarity. This quality checking was done daily 
after data collection and correction was made before the 
next data collection measure. Data clean up and cross-
checking was done before analysis. After data collection, data 
was stored in a secured place to maintain confidentiality and 
backup of the data was stored in different areas not to lose 
the data. Each questionnaire was coded separately before 
analysis. 
Data processing and analysis 
All returned questionnaires were checked for completeness 
and consistency of responses visually. The collected data 
were coded and entered in to EPI INFO version 7 and 
exported to STATA (version 12) statistical software. Data 
were cleaned and analyzed using STATA version 12.  During 
descriptive analysis, continuous variables were summarized 
using mean, median and standard deviation while 
categorical variables were summarized using proportions 
and then presented in tables and graphs. Bi-variable 
analyses were done to test for associations between the 
dependent variable (loss to follow up) and independent 
variables. Before inclusion of predictors to multivariable Cox 
regression analysis, fulfillment of model assumption was 
checked using goodness -of- fit test or Schoenfeld residuals 
(phtest). Multi co- linearity was checked using Variance 
Inflation Factors (VIF) or tolerance of explanatory variables. 
Survival analysis using life table and Kaplan-Meier survival 
curve were used to assess survival status of loss to follow up. 
The log rank test was used to assess presence of significant 
difference in survival status of loss to follow up between 
categorical socio demographic and clinical characteristics. 
Cox regression model was employed to measure the effect of 
each variable on the hazard of loss to follow up after 
adjusting for other variables at 95% confidence level. A 
variable with P-value < 0.05 in multivariable Cox regression 
analysis was considered as a factor associated with the loss 
to follow up at 95% confidence level.  
Ethical Consideration 
This study was approved by the ethical review committee of 
University of Gondar. Permission was obtained from the all 
the eight hospitals and the names of patients were not 
recoreded in our data extraction form and their unique ART 
numbers were kept locked for better confidentiality.   
RESULTS 
Socio-demographic characteristics 
A total of 1246 adult HIV/AIDS patients participated in the 
study. The mean age of participants (mean [±SD]) was 32.98 
(±.8.739) years, ranging from 15 to 73 years. Fifty one 
percent of patients were males, half belonged to less than 32 
years of age, one third of them had attended secondary 
education, and more than one third were unemployed. One 
third patients were from Felege Hiwot referral hospital 
(Table 1). 
 
 
 
 
 
Amhara Regional Hospitals 
University Gondar 
Referral hospital 
n=148 
Dessie referral 
hospital  n=389 
Felege Hiwot Referral 
Hospital n=412 
Finot Selem general 
hospital n=35 
Woldia general 
hospital n=164 
Debre Markos 
referral hospital 
n=49 
Debra tabor general 
hospital n=24 
Debre Berhan referral 
hospital n=25 
Total sample N= 1,246 
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Table 1: Socio-demographic characteristic of HIV patients on second line ART in Amhara region Hospitals, Ethiopia 
Variable Number Percent 
Sex                                         Female  590 48.72 
                                                Male 621 51.28 
Age patients                            
                                                <32 
 
673 
 
54.27 
                                                32-40  369 29.76 
                                                >40 198 15.97 
Education          
                                               No education 
 
378 
 
32.09 
                                               Primary   244 20.71 
                                               Secondary   414 35.14 
                                               Tertiary  142 12.05 
Occupation                        Unemployed   437 37.67 
                                                Government  
                                                Non government 
299 
25 
25.78 
2.16 
                                                Private  82 7.07 
                                                Others*  317 27.33 
Hospital/ facility   
              Debre Berhan Referral hospital              
              Debre Markos Referral hospital              
              Debre Tabor general hospital 
              Dessie referral hospital 
              Felege Hiwote referral hospital 
              Finote Salem general hospital 
              Gondar University  referral hospital 
 
25 
49 
24 
389 
412 
35 
148 
 
2.01 
3.93 
1.93 
31.22 
33.07 
2.81 
11.88 
              Woldia general hospital 164 13.16 
                                
 
Baseline Clinical Characteristics  
Seven hundred thirty eight (63%) of patients had history of 
past opportunistic infection; around 666 (55.5%) of the 
participants have CD4 cell count less than 100 cells/ml at 
baseline. About 638 (52.7%) of the patients were under 
WHO stage III. About 391 (41%) of patients were having 
poor adherence and majority (33.39%) of participate take 
drug type of 2g=TDF-3TC-LPV/r (Table 2). 
Incidence of lost to follow-up  
The study participants were assessed retrospectively with a 
total follow up of 38,956.7 person-months. The overall 
incidence density of loss to follow up was 1.67 losses to 
follow up per 1000 persons-months. The cumulative 
incidence of losses to follow up was 5.41% over the entire 
period of follow-up. Others cumulative incidences like death 
and transfers out were 10.99% and 10.02 %, respectively. 
The remaining 73.59 % of the participants were actively on 
treatment when the study ended. 
Those who took CPT (blue line) and those who did not take it 
(red line) were statistically significantly different (p-value = 
0.0319) with regard to the incidence of loss to follow up.  
The graph also showed a constantly diverging patter except 
at the end of the follow up period where less emphasis 
would be given due to the smaller sample size (Figure 2). 
   
 
Figure 2: Keplan-Meier estimate of the survival of patients on second line ART from LTFU grouped by Co-trimoxazole intake status 
in Amhara region hospitals, North Ethiopia, 2016 
Mohammed et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):52-59 
ISSN: 2250-1177                                                                                  [56]                                                                                 CODEN (USA): JDDTAO 
Table 2: Clinical characteristics of second line regimens in ART adult living with HIV /AIDS Amhara region hospitals 
Variable Number Percent 
Opportunistic infection                   
                                               Yes 
 
738 
 
62.97 
                                               No 434 37.03 
Baseline functional status           
                                              Working 
 
744 
 
62.16 
                                              Ambulatory 394 32.92 
                                              Bedridden 59 4.93 
WHO stage                               
                                               Stage  I 
 
129 
 
10.65 
                                               Stage II 240 19.82 
                                               Stage III 638 52.68 
                                              Stage IV 204 16.85 
Baseline CD4 count                  
                                            <100 
 
666 
 
55.55 
                                            >=100 533 44.45 
T stage of switch               
                                          T stage I 
 
630 
 
52.72 
                                          T stage II 123 10.29 
                                          T stage III 360 30.13 
                                          T stage IV 82 6.86 
Reason of switch            
                                         Clinical failure 
 
338 
 
28.60 
                                         Immunologic failure 546 46.19 
                                         Virologic failure 253 21.40 
                                         Drug toxicity 39 3.30 
                                         Others* 6 0.51 
Adherence                                
                                         Poor 
 
391 
 
41.55 
                                         Fair 240 25.50 
                                         Good 310 32.94 
CPT given                                
                                        No 
 
329 
 
27.69 
                                        Yes 859 72.31 
INH given                                   
                                        No 
 
885 
 
75.71 
                                        Yes 284 24.29 
Reason eligible for ART          
                                        Clinical 
 
265 
 
21.88 
                                        CD4 count 856 70.69 
                                        Viral load 13 1.07 
                                        TLC 3 0.25 
                                        Transfer in 74 6.11 
Baseline weight                            
                                     <45 
                                     45-60 
                                     >60 
Second line regimen 
                                 2a=ABC-DDI-LPV/r 
                                 2b=ABC-DDI-NFV 
                                 2c=TDF-DDI-LPV/r 
                                 2d=TDF-DDI-NFV 
                                 2e=AZT-3TC-LPV/r 
                                 2f=AZT-3TC-ATV/r 
                                 2g=TDF-3TC-LPV/r 
                                 2h=TDF-3TC-ATV/r 
                                 2i=ABC-3TC-LPV/r 
                                 2j=ABC-3TC-ATV/r 
                                 2k=ABC-DDI-ATV/r 
                                 2l=Others** 
 
360 
694 
150 
 
203 
4 
20 
4 
133 
112 
406 
136 
87 
58 
6 
47 
 
29.90 
57.64 
12.46 
 
16.69 
0.33 
1.64 
0.33 
10.94 
9.21 
33.39 
11.18 
7.15 
4.77 
0.49 
3.87 
 
Factors associated with loss to follow up 
To determine the effect of factors on time to lost to follow up, 
both bi-variable and multi-variable Cox regression was 
fitted. Covariates having p-values of more than 0.2 in the bi-
variable analsis that included occupation, educatopnal level, 
history of opportunistic infection, past TB treatment, CPT, 
and INH given were excluded from the multivariable Cox 
regression.  
In the multi variable Cox regression Age, weight ,CD4 count, 
T stage at switch and Reason of switch were not estimated to 
Mohammed et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):52-59 
ISSN: 2250-1177                                                                                  [57]                                                                                 CODEN (USA): JDDTAO 
be independent predictors of time to loss to follow up. In the 
multi variable Cox regression, male gender was posatively 
and significantly associated with time to loses to follow up. 
But, ambulatory baseline functional status, good adherence, 
and drugs other than 2k were inversely  associated with time 
to loss to follow  up.  
The hazard of loss to follow up for male is 2 times higher 
when compare to females (AHR= 2.135, 95% CI 1.053- 
4.330). Ambulatory functional status decreased the hazard of 
loss to follow up by 80.3 % as compared to those having 
working functional status (AHR=0.1967, 95% CI 0.049-0 
.794). Those who have good adherence decreased the hazard 
of loss to follow up by 55.8 % as compared to those having 
poor adherence (AHR=0.442, 95% CI 0.198- 0.989). Patients 
who took drug type 2a=ABC-DDI-LPV/r (Abacavir-
didanosine-Lopinavir/ritonavir)decreased the hazard of loss 
to follow up by 93.9 % as compared to those who took drug 
type 2k=ABC-DDI-ATV/r(Atazanovir/ritonavir) (AHR=0.061, 
95% CI 0.006-0.594). Those who took drug type 2e=AZT-
3TC-LPV/r decreased the hazard of loss to follow up by 93.5 
% as compared to those who took 2k=ABC-DDI-ATV/r 
(AHR= 0.065, 95% CI 0.005-0.825) (Table 3). 
 
Table 3:  Bi-variable and multi -variable Cox regression analysis for time to loss to follow up in 8 hospitals in Amhara region of 
Ethiopia, 2016 
Variable   Loss to follow up 
Yes  No  CHR(95% CI) AHR(95% CI) 
Gender                                 
             Female                                        
             Male 
Functional status 
 
   28(4.8) 
   33(5.3) 
 
 
557(95.2) 
586(94.7)  
     
 
1 
1.0713(0.6414- 1.7895) 
 
 
1 
2.135 (1.053- 4.330) 
 
             Working  44(  5.96) 694(94.0)   1 1 
             Ambulatory 15 (3.8) 378(96.2) 0.501 (0.274 -0.916) 0.1967(0.049- 0 .794) 
             Bedridden 2(3.4) 57(96.6) 0.696 (0.168 -  2.881) 0.145 (0.0071- 2.956) 
 Age category     
             <32  36 (5.4)  630(94.6) 1 1 
             32-40  20 (5.43)  348(94.6) 0.887(0.508- 1.547) 1.387 (0.677 - 2.843 ) 
             >40  10 (5.05 188 (94.95        0.727 (0.350- 1.512) 0.810 (0.318 -2.066) 
Reason of switch     
             Clinical failure 21  (6.2)  317(93.8)           1 1 
             Immunological failure  29 (5.4) 511 (94.6) 0.708(0.402 -1.248) 0.733 (0.355-1.511) 
             Virologic   7 (2.8) 245 (97.2)  0.431(0.174-1.069) 0.353 (0.1198- 1.043) 
             Drug toxicity   2 (5.1) 37 (94.8) 0.603 (0.140-2.593) 0.321 (0.0356- 2.889) 
T stage at switch     
              T stage one  31 (5) 593 (95) 1 1 
              T stage two 10 (8.1) 113(91.9) 1.446 (0.705 -2.969) 1.623 ( 0.6288- 4.189) 
              T stage three 17 (4.7) 342(95.3) 0.664(0.361-1.223) 0.7089(0.323- 1.553) 
              T stage four 
Baseline CD4 count 
             <100                                         
             >=100    
 Adherence level 
              Poor   
              Fair  
              Good  
Second regimen 
         2a=ABC-DDI-LPV/r 
         2e=AZT-3TC-LPV/r 
         2f=AZT-3TC-ATV/r 
         2g=TDF-3TC-LPV/r 
        2h=TDF-3TC-ATV/r 
        2i=ABC-3TC-LPV/r 
        2k=ABC-DDI-ATV/r 
        2l=Others* 
Baseline weight 
         <45 
         45-60 
         >60     
       
61 (5.1) 
 
27(4.1) 
30(5.7 ) 
    
27(7) 
11(4.6) 
9(2.9) 
 
16 (7.9) 
 8(6) 
4(3.67) 
21(5.2) 
9(6.7) 
2(2.3) 
5(16.67) 
3(6.4) 
 
20( 5.6) 
31(4.5) 
10(6.7) 
1,127(94.9 
 
636(95.9)  
499(94.3) 
 
360(93) 
229(95.4) 
301 (97.1) 
 
186(92.1) 
125 (94) 
105(96.3) 
385(94.8) 
126 (93.3) 
85(97.7) 
25(83.33) 
44(93.6) 
 
336 (94.3) 
661(95.5) 
139(93.3) 
0.537 (0.163 -1.766) 
 
 1 
1.273(0.7482- 2.167) 
 
1 
0.706(0.348-1.434) 
0.433(0.2031- 0.9264) 
 
0.087(0.0111- 0.682) 
0.144(0.0174- 1.187) 
0.208(0.023- 1.878) 
0.069(0.0089-0.527) 
0.358(0.045- 2.847) 
0.073(0.006-0 .821) 
1 
0.059(0.0058-0.595) 
 
1 
0.802(0.453-1.419) 
1.07(  0.50- 2.287) 
1.109 (0.314-3.912) 
 
1 
1.406 (0.718- 2.753) 
 
1 
0.717 (0.320-1.604) 
0.442 (0.198- 0.989) 
 
0.061 (0.006-0.594) 
0.065 (0.005-0.825) 
0.196 (0.017-  2.263) 
0.055(0.006- 0.512) 
0.507(0.051-  5.069) 
0.085(0.007-  1.071) 
1 
0 .043 (0.003-0 .621) 
 
1 
0.602 (0.271-1.338) 
0.826 (0.279- 2.445) 
 
DISCUSSION 
In this study, the cumulative incidence rate of LTFU in ART 
care was 65 (5.41 %). This finding is lower than findings in 
India6, SSA7, Nigeria8, South Africa9, and Cameron10. It is also 
lower than studies done in southern Ethiopia hospitals11, 
Hadiya zone12, and Ethiopian public hospital clinics13 The 
differences could be due to variations in study design and 
patient time follow-ups. However, another study comprising 
different regions including SSA, Asia, Latin America and 
Eastern Europe 15 had got comparable finding with the 
current study. 
The frequencies under the Loss to follow up column are the number of participants used in the bi-variable analyses  
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Regarding factors, male gender was a positive significant 
predictor for losses to follow up and good adherence, 
ambulatory functional status, and second line regimen drug 
types of 2a. 2e and 2g had an inverse association with the 
hazard of LTFU. In the current study, the hazard of loss to 
follow among males  was 2.1 times  higher  as compared to 
females (AHR = 2.135, 95% CI 1.053- 4.330). A similar 
finding was reported by a study conducted in India6, 
Cameron10 and north Ethiopia16. This could be explain by the 
fact that men usually travel for work particularly in 
professions of truck drivers, day working, and due to 
migrant agricultural works which keeps them away from 
their home likewise their medication17.  
This study showed that ambulatory functional status 
decreased the hazard of loss to follow up by 80.3% as 
compared to those participants whose status was working 
(AHR=0.1967, 95% CI 0.049-0.794). Similar study done in 
southern Ethiopia support this study11. The possible 
justification for this could be due to their routine duety in the 
working group that could affect negatively their adharence 
or follow up while it could creat a better condition for those 
who were ambulatory to attend strictly their treatment.   
In this study, those who have good adherence decreased the 
hazard of loss to follow up by 55.8 % as compared to those 
having poor adherence. A similar finding was reported by a 
study conducted in Nigeria18. Our findings highlight the need 
for strengthening of treatment adherence by counselors and 
support groups to minimize LTFU and this could be an 
indication of the integrity of better adherence and reduced 
LTFU that may probably work for the synergy of better 
health. 
Age was not a significant risk factor of time loss to follow up 
in this study. On contrary to this, studies  done in south 
Africa19, Nigeria18 and southern Ethiopia11 showed that the 
younger age  was significantly related with higher level of 
loss to follow up. The contradiction of these studies could be 
due to the variation in age distribution of those studies 11,18,19  
when comared to the current study .  
In this study, CD4 count was not an independent predictor of 
time to LTFU. However, other studies done in India 6 and 
southern Ethiopia 20 showed that the lower baseline CD4 cell 
count was risk factor for LTFU. On the other hand studies 
conducted in SSA7 and Ethiopia rural hospital 14 showed that 
higher CD4 cell count increased the risk of LTFU. The 
contradiction in these studies may be due to the difference in 
confounding variables that were not controlled by the 
respective studies as it could affect the true effect of CD4 
count on LTFU.    
In the current study, taking drug types of 2a, 2e and 2g 
reduced the hazard of LTFU when compared with those who 
took drug type 2k. This disparity among drugs with regard to 
the status of LTFU might be associated with the difference in 
the effectiveness of drugs in improving health which could 
subject itself to further research.   
Limitation 
This  study included only adults beyond age 15 who were on  
ART;  and  this group of particpants might not represents  
individuals whose age was less than 15.The other limitation 
of the current study is that the possible outcomes of LTFU 
patients might not have been accurately captured as patients 
who were classified as LTFU might have actually died or 
been cared for in other facilities.   
CONCLUSION  
The incidence of LTFU in Amhara region hospitals was low. 
Loss to follow up was negatively  associated with female 
gender, ambulatory  baseline functional status, adherence, 
and second line drug types of 2a, 2e, and 2g. Close follow up 
is recommended to minimize LTFU and improve treatment 
outcomes of adults on ART with due emphasis for males with 
working functional status and poor adherence level. We also 
recommend further research on the effect of drug types by 
acertaining whether the reduction in LTFU for patients who 
took drug types of 2a, 2e, and 2g is associaed with improved 
or worsened health outcomes by trafcking closely lost 
patients.    
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